Literature DB >> 15857754

Role of the proteasome in the regulation of estrogen receptor alpha turnover and function in MCF-7 breast carcinoma cells.

Ioanna Laïos1, Fabrice Journé, Denis Nonclercq, Doris Salazar Vidal, Robert-Alain Toillon, Guy Laurent, Guy Leclercq.   

Abstract

Estrogen receptor alpha (ER) turnover in MCF-7 cells was assessed by pulse chase analysis and measurement of ER steady-state level. In untreated cells, degradation of (35)S-labeled ER was characterized by a slow phase followed by a more rapid decline. Without ligand, ER elimination was totally compensated by synthesis which maintained receptor homeostasis. Estradiol (E(2)) and the pure antiestrogen RU 58,668 abolished the slow phase of ER breakdown and enhanced the degradation of neosynthesized ER, producing a low ER steady-state level. By contrast, the partial antiestrogen OH-Tam was ineffective in this respect and caused ER accumulation. Regardless of the conditions, ER breakdown was abolished by proteasome inhibition (MG-132). ER ligands decreased cell capacity to bind [(3)H]E(2), even in the presence of MG-132, indicating that the regulation of ER level and E(2) binding capacity occurs through distinct mechanisms. MG-132 partially blocked the basal transcription of an ERE-dependent reporter gene and modified the ability of E(2) to induce the expression of the latter: the hormone was unable to restore the transactivation activity measured without MG-132. RU 58,668 and OH-Tam failed to enhance the inhibitory action of MG-132, suggesting that a loss of basal ER-mediated transactivation mainly affects the stimulatory effect of estrogens. Overall, our findings reveal that ER steady state level, ligand binding capacity and transactivation potency fit in a complex regulatory scheme involving distinct mechanisms, which may be dissociated from each other under various treatments.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15857754     DOI: 10.1016/j.jsbmb.2005.02.005

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  22 in total

1.  Characterization of the pharmacophore properties of novel selective estrogen receptor downregulators (SERDs).

Authors:  Karen J Kieser; Dong Wook Kim; Kathryn E Carlson; Benita S Katzenellenbogen; John A Katzenellenbogen
Journal:  J Med Chem       Date:  2010-04-22       Impact factor: 7.446

2.  Estradiol-estrogen receptor: a key interplay of the expression of syndecan-2 and metalloproteinase-9 in breast cancer cells.

Authors:  Olga Ch Kousidou; Aikaterini Berdiaki; Dimitris Kletsas; Alexandros Zafiropoulos; Achilleas D Theocharis; George N Tzanakakis; Nikos K Karamanos
Journal:  Mol Oncol       Date:  2008-06-18       Impact factor: 6.603

3.  Palmitoylation regulates 17β-estradiol-induced estrogen receptor-α degradation and transcriptional activity.

Authors:  Piergiorgio La Rosa; Valeria Pesiri; Guy Leclercq; Maria Marino; Filippo Acconcia
Journal:  Mol Endocrinol       Date:  2012-03-22

4.  Phosphorylation by p38 mitogen-activated protein kinase promotes estrogen receptor α turnover and functional activity via the SCF(Skp2) proteasomal complex.

Authors:  Shweta Bhatt; Zhen Xiao; Zhaojing Meng; Benita S Katzenellenbogen
Journal:  Mol Cell Biol       Date:  2012-03-19       Impact factor: 4.272

5.  The catalytic subunit of the proteasome is engaged in the entire process of estrogen receptor-regulated transcription.

Authors:  Hua Zhang; Luyang Sun; Jing Liang; Wenhua Yu; Ying Zhang; Yan Wang; Yupeng Chen; Ruifang Li; Xiaojing Sun; Yongfeng Shang
Journal:  EMBO J       Date:  2006-09-07       Impact factor: 11.598

6.  Estrogen receptor-alpha hinge-region lysines 302 and 303 regulate receptor degradation by the proteasome.

Authors:  Nicholas B Berry; Meiyun Fan; Kenneth P Nephew
Journal:  Mol Endocrinol       Date:  2008-04-03

7.  Whole transcriptome analysis of the ERα synthetic fragment P295-T311 (ERα17p) identifies specific ERα-isoform (ERα, ERα36)-dependent and -independent actions in breast cancer cells.

Authors:  George Notas; Marilena Kampa; Vassiliki Pelekanou; Maria Troullinaki; Yves Jacquot; Guy Leclercq; Elias Castanas
Journal:  Mol Oncol       Date:  2013-02-20       Impact factor: 6.603

8.  OTU Domain-containing ubiquitin aldehyde-binding protein 1 (OTUB1) deubiquitinates estrogen receptor (ER) alpha and affects ERalpha transcriptional activity.

Authors:  Vladimir Stanišić; Anna Malovannaya; Jun Qin; David M Lonard; Bert W O'Malley
Journal:  J Biol Chem       Date:  2009-04-21       Impact factor: 5.157

9.  Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines.

Authors:  Fabrice Journe; Carole Chaboteaux; Nicolas Magne; Hugues Duvillier; Guy Laurent; Jean-Jacques Body
Journal:  Breast Cancer Res       Date:  2005-12-12       Impact factor: 6.466

10.  Regulatory function of the P295-T311 motif of the estrogen receptor alpha - does proteasomal degradation of the receptor induce emergence of peptides implicated in estrogenic responses?

Authors:  Dominique Gallo; Iman Haddad; Guy Laurent; Joëlle Vinh; Françoise Jacquemotte; Yves Jacquot; Guy Leclercq
Journal:  Nucl Recept Signal       Date:  2008-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.